- Common Stocks and Uncommon Profits, Phil Fisher  This is why we care about a company's annual R&D spending as a percentage of sales, its trend and comparison with competitors and the track record of pipeline outcome.The California-based company had been dominating the lucrative robotic med-tech space for a long time until competitors finally started to unveil their counterparts in recent years (including the much-awaited Hugo RAS system from Medtronic (NYSE:MDT)).